NCT03630640View on ClinicalTrials.gov

Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation

PHASE2CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

August 19, 2023

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Nivolumab Injection [Opdivo]

Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP

Trial Locations (1)

93140

Hôpital Jean Verdier, Bondy

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER